0HF9 Stock Overview
A biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Amicus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.35 |
| 52 Week High | US$14.57 |
| 52 Week Low | US$9.04 |
| Beta | 0.68 |
| 11 Month Change | 9.03% |
| 3 Month Change | 13.08% |
| 1 Year Change | -2.24% |
| 33 Year Change | -5.18% |
| 5 Year Change | n/a |
| Change since IPO | -29.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HF9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -3.3% | -0.9% | -0.9% |
| 1Y | -2.2% | -14.9% | 8.6% |
Return vs Industry: 0HF9 exceeded the UK Biotechs industry which returned -12.7% over the past year.
Return vs Market: 0HF9 underperformed the UK Market which returned 10.2% over the past year.
Price Volatility
| 0HF9 volatility | |
|---|---|
| 0HF9 Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HF9's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HF9's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 517 | Brad Campbell | amicusrx.com |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline.
Amicus Therapeutics, Inc. Fundamentals Summary
| 0HF9 fundamental statistics | |
|---|---|
| Market cap | US$3.40b |
| Earnings (TTM) | -US$119.54m |
| Revenue (TTM) | US$455.66m |
7.5x
P/S Ratio-28.5x
P/E RatioIs 0HF9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HF9 income statement (TTM) | |
|---|---|
| Revenue | US$455.66m |
| Cost of Revenue | US$46.10m |
| Gross Profit | US$409.56m |
| Other Expenses | US$529.09m |
| Earnings | -US$119.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 89.88% |
| Net Profit Margin | -26.23% |
| Debt/Equity Ratio | 293.5% |
How did 0HF9 perform over the long term?
See historical performance and comparison